DrugPatentWatch Database Preview

Sb Pharmco Company Profile

« Back to Dashboard

What is the competitive landscape for SB PHARMCO, and what generic alternatives to SB PHARMCO drugs are available?

SB PHARMCO has three approved drugs.

There are two US patents protecting SB PHARMCO drugs.

There are one hundred and nine patent family members on SB PHARMCO drugs in forty-six countries and thirty-nine supplementary protection certificates in twelve countries.

Summary for Sb Pharmco

International Patents:	109
US Patents:	2
Tradenames:	3
Ingredients:	3
NDAs:	3

Drugs and US Patents for Sb Pharmco

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-003	Oct 10, 2002		DISCN	Yes	No	8,236,345		Y
Sb Pharmco	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-002	May 25, 1999	AB	RX	Yes	No	7,358,366*PED				Y
Sb Pharmco	AVANDARYL	glimepiride; rosiglitazone maleate	TABLET;ORAL	021700-004	Mar 30, 2007		DISCN	Yes	No	7,358,366*PED				Y
Sb Pharmco	AVANDARYL	glimepiride; rosiglitazone maleate	TABLET;ORAL	021700-005	Mar 30, 2007		DISCN	Yes	No	7,358,366*PED				Y

Expired US Patents for Sb Pharmco

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-002	Oct 10, 2002	5,965,584*PED
Sb Pharmco	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-004	May 25, 1999	6,288,095*PED
Sb Pharmco	AVANDARYL	glimepiride; rosiglitazone maleate	TABLET;ORAL	021700-001	Nov 23, 2005	5,002,953*PED
Sb Pharmco	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-002	May 25, 1999	6,288,095*PED

Paragraph IV (Patent) Challenges for SB PHARMCO drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	1 mg/ 500 mg, 2 mg/ 500mg, 4 mg/ 500 mg, 2 mg/ 1000 mg and 4 mg/ 1000 mg		2004-10-22
	Tablets	8 mg/2 mg and 8 mg/4 mg		2008-05-30
	Tablets	1 mg/4 mg, 2 mg/4 mg and 4 mg/4 mg		2006-12-22

International Patents for Sb Pharmco Drugs

Country	Document Number	Estimated Expiration
Australia	771342
Croatia	P20010774
Mexico	PA02005005
Peru	00452001

Supplementary Protection Certificates for Sb Pharmco Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
/2000	Austria		PRODUCT NAME: ROSIGLITAZONE MALEAT; NAT. REGISTRATION NO/DATE: EU/1/00/137/001 - EU/1/00/137/012 20000711; FIRST REGISTRATION: LI 55176 19990929
00524	Netherlands		PRODUCT NAME: COMBINATIE VAN SAXAGLIPTINE EN METFORMINE, DESGEWENST IN DE VORM VAN FARMACEUTISCH AANVAARDBARE AFGELEIDEN DAARVAN; NAT. REGISTRATION NO/DATE: EU/1/11/731/001-012 20111124; FIRST REGISTRATION:
1730131/02	Switzerland		PRODUCT NAME: EMPAGLIFLOZIN UND METFORMINHYDROCHLORID; REGISTRATION NO/DATE: SWISSMEDIC 65570 12.11.2015
00357	Netherlands		PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Sb Pharmco